Integrated prognostic value of MRD and cytogenetics in adolescent and adult B‐cell acute lymphoblastic leukaemia
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70281 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jiayan Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, College of Medicine, Institute of Hematology, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 35 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province Grant/AwardNumber : LMS25H080003.
Abstract (Originalsprache)
B‐cell acute lymphoblastic leukaemia (B‐ALL) in adolescents and adults remains challenging due to high relapse rates and suboptimal outcomes. Although minimal residual disease (MRD) and cytogenetic risk classification are independent prognostic indicators for B‐ALL in adolescents and adults, their combined utility remains under explored. This retrospective study analysed 609 adolescent and adult patients with B‐ALL to evaluate the integrated prognostic value of MRD at end of induction (MRD1) and after first consolidation (MRD2), combined with cytogenetic risk stratification (standard risk [SR] vs. poor risk [PR]). Although cytogenetic risk alone was not an independent prognostic factor, MRD positivity at either time point significantly predicted inferior 5‐year RFS and OS in PR patients. Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) improved outcomes overall; however, PR patients with MRD2 positivity remained at high risk of relapse post‐transplant. Multivariate analysis identified MRD1 and MRD2 as independent predictors of both relapse (RFS HR = 2.048) and mortality (OS HR = 1.979) in PR patients (all p < 0.01). These results demonstrate that combining MRD assessment with cytogenetic risk improves risk stratification, precisely identifying poor‐risk patients with persistent MRD who may benefit from treatment intensification, including novel strategies post‐transplant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital, College of Medicine, Institute of Hematology, Zhejiang University, Hangzhou, China.
- Key Laboratory of Hematologic Malignancies, Diagnosis and Treatment, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Clinical Research Center for Hematological Disorders, Hangzhou, China.
- Zhejiang University Cancer Center, Zhejiang University, Hangzhou, China.
- College of Medicine, Zhejiang University, Hangzhou, China.
ORCID-Profile: Lin Liu, Jie Jin, Hongyan Tong
Förderung
- Natural Science Foundation of Zhejiang Province Grant/AwardNumber : LMS25H080003
Zitieren
APA
Gu, J., Wang, J., Liu, L., Zhang, Y., Ghanad, P., Goli, M. M., Bao, C., Jin, J., & Tong, H. (2025). Integrated prognostic value of MRD and cytogenetics in adolescent and adult B‐cell acute lymphoblastic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70281
Vancouver
Gu J, Wang J, Liu L, Zhang Y, Ghanad P, Goli MM, et al. Integrated prognostic value of MRD and cytogenetics in adolescent and adult B‐cell acute lymphoblastic leukaemia. British Journal of Haematology. 2025. doi:10.1111/bjh.70281
BibTeX
@article{Gu2025,
author = {Gu, Jiayan and Wang, Jinghan and Liu, Lin and Zhang, Yi and Ghanad, Parnia and Goli, Maryam Maleki and Bao, Chenhui and Jin, Jie and Tong, Hongyan},
title = {Integrated prognostic value of MRD and cytogenetics in adolescent and adult B‐cell acute lymphoblastic leukaemia},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70281}
}
EUVIMED